Literature DB >> 26225712

Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis.

Di-Ya Wang1, Lei Liu, Xing-Shun Qi, Chun-Ping Su, Xue Chen, Xu Liu, Jiang Chen, Hong-Yu Li, Xiao-Zhong Guo.   

Abstract

BACKGROUND: A systematic review and meta-analysis were performed to compare the post-recurrence survival with hepatic re-resection versus transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after initial resection.
MATERIALS AND METHODS: All relevant papers were searched via PubMed, EMBASE, and Cochrane Library databases. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Subgroup analysis was performed according to country. Sensitivity analysis was performed in studies which clearly reported the recurrent regions, in moderate/high-quality studies, in studies published in full-text form, and in studies published after 2005.
RESULTS: In total, twelve papers were included in our study. Five and seven of them were of moderate- and poor-quality, respectively. The overall meta-analysis demonstrated a statistically significantly higher post-recurrence survival in the hepatic re-resection group than in those undergoing TACE (HR=0.64, 95%CI=0.52-0.79, P<0.0001). Heterogeneity was statistically significant and statistical significance remained in the subgroup analysis. Sensitivity analyses were also consistent with the overall analysis.
CONCLUSIONS: Hepatic re-resection might provide a better post-recurrence survival than TACE for recurrent HCC after initial resection. However, considering the low quality of published studies and the potential bias of treatment selection, further randomized trials should be warranted to confirm these findings.

Entities:  

Mesh:

Year:  2015        PMID: 26225712     DOI: 10.7314/apjcp.2015.16.13.5573

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma.

Authors:  Junichi Shindoh; Yusuke Kawamura; Yuta Kobayashi; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Masaji Hashimoto
Journal:  J Gastrointest Surg       Date:  2019-06-12       Impact factor: 3.452

Review 2.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

3.  Treatment and outcomes of recurrent hepatocellular carcinomas.

Authors:  Gaëtan-Romain Joliat; Pierre Allemann; Ismail Labgaa; Nicolas Demartines; Nermin Halkic
Journal:  Langenbecks Arch Surg       Date:  2017-05-11       Impact factor: 3.445

Review 4.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

Review 5.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

6.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

7.  Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence.

Authors:  Qiang Tao; Wei He; Binkui Li; Yun Zheng; Ruhai Zou; Jingxian Shen; Wenwu Liu; Yuanping Zhang; Yunfei Yuan
Journal:  J Cancer       Date:  2018-07-16       Impact factor: 4.207

8.  Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection.

Authors:  Kun-Ming Chan; Tsung-Han Wu; Chih-Hsien Cheng; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Wei-Chen Lee
Journal:  Biomed J       Date:  2019-10-29       Impact factor: 4.910

9.  Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  Michinori Matsumoto; Katsuhiko Yanaga; Hiroaki Shiba; Shigeki Wakiyama; Taro Sakamoto; Yasuro Futagawa; Takeshi Gocho; Yuichi Ishida; Toru Ikegami
Journal:  Ann Gastroenterol Surg       Date:  2021-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.